Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 16, 2024; 12(29): 6307-6313
Published online Oct 16, 2024. doi: 10.12998/wjcc.v12.i29.6307
Combination treatment with telitacicept, mycophenolate mofetil and glucocorticoids for immunoglobulin A nephropathy: A case report
Yan Shen, Jin Yuan, Shuang Chen, Yong-Feng Zhang, Ling Yin, Qin Hong, Yan Zha
Yan Shen, Jin Yuan, Shuang Chen, Yong-Feng Zhang, Ling Yin, Qin Hong, Yan Zha, Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou Province, China
Author contributions: Shen Y contribute to patient management, manuscript writing; Yuan J contribute to clinical treatment of the patient; Chen S contribute to data analysis and interpretation; Zhang YF and Yin L contribute to Collection of experimental data from the patient; Hong Q contribute to analysis and interpretation of pathological images; Zha Y contribute to research design and conceptualization, including formulating the research question and designing the study.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All authors have no conflicts of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Zha, MD, Chief Physician, Department of Nephrology, Guizhou Provincial People's Hospital, Baoshan South Road, Nanming District, Guiyang 550002, Guizhou Province, China. bookworm2023@163.com
Received: May 3, 2024
Revised: June 4, 2024
Accepted: August 1, 2024
Published online: October 16, 2024
Processing time: 117 Days and 14.5 Hours
Core Tip

Core Tip: Telitacicept reduces B cell activation and abnormal immunoglobulin A (IgA) antibody production by inhibiting the activity of B lymphocyte stimulator and a proliferation-inducing ligand, thereby decreasing IgA deposition in the glomeruli and local inflammatory response. This mechanism suggests that Telitacicept has potential efficacy in the treatment of IgA nephropathy. This paper reports a successful clinical case of using Telitacetin to treat IgA nephropathy.